C4X Discovery Holdings PLC PDMR Shareholding (6867E)
October 22 2018 - 2:00AM
UK Regulatory
TIDMC4XD
RNS Number : 6867E
C4X Discovery Holdings PLC
22 October 2018
C4X Discovery Holdings plc
("C4XD" or the "Company")
PDMR Shareholdings
22 October 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that Dr Craig Fox,
Chief Scientific Officer, has today purchased 5,900 ordinary shares
of 1 pence each in the Company ("Ordinary Shares"), at a price of
86.7 pence per Ordinary Share (the "Dealing"). Following the
Dealing, Dr Craig Fox holds 7,183 Ordinary Shares.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and/or persons closely
associated with them:
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Craig Fox
------------------------------------------------------------ -----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------------------
Chief Scientific Officer, Director
a) Position/status
------------------------------------------------------------ -----------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------ -----------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------------
a) Name C4X Discovery Holdings plc
------------------------------------------------------------ -----------------------------------------
b) LEI 213800UHNL82E323O870
------------------------------------------------------------ -----------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument 1p ordinary shares
Identification code
ISIN GB00BQQ2RV18
------------------------------------------------------------ -----------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------------------------------ -----------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Share Volume(s)
86.7p 5,900
------------------------------------------------------------ -----------------------------------------
d) Aggregated information Price Volume(s)
GBP5,115.30 5,900
----------
------------------------------------------------------------ -----------------------------------------
e) Date of the transaction 19 October 2018
------------------------------------------------------------ -----------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------------ -----------------------------------------
Name of authorised official of issuer responsible for making
notification: Brad Hoy, Chief Financial Officer of the Company.
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications 020 3709 5700
Mary-Jane Elliott, Matthew Neal, Chris Gardner
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards pre-clinical licensing
discussions. In selecting and executing new drug discovery
programmes, C4X Discovery focuses on high-value disease areas that
are the subject of significant licensing activity and will continue
to also maximise value from opportunistic areas such as addiction
and diabetes. The Company recently signed a licensing agreement
with Indivior for a pre-clinical addiction programme worth up to
$294 million.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
--ENDS----
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHMBBBTMBMTTPP
(END) Dow Jones Newswires
October 22, 2018 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2024 to Jun 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jun 2023 to Jun 2024
